Senior Connect Acquisition Corp. I (NASDAQ:SNRH) announced this afternoon that it has signed a non-binding letter of intent (LOI) to combine with precision medicine company Avellino Lab USA, Inc.
Under the terms of the LOI, the parties would become a combined entity, with Avellino’s existing equityholders exchanging their shares in Avellino for equity in the combined company. Although details on the proposed merger remain limited, Senior Connect expects to disclose further information on the deal once a definitive agreement is executed, which is expected to occur early in the first quarter of 2023.
Avellino is a genetics-based diagnostics and research company that is focused on advancing precision health using machine learning to unlock the potential for research, development and commercialization of diagnostics and therapeutics. Avellino’s main business is the aggregation, curation, and analysis of genetic data to provide solutions for early detection of disease states in the areas of ophthalmology, oncology and infectious disease.
The precision medicine company has a strong track record of diagnosing genetic conditions, initially focused on corneal dystrophies and other inherited diseases in ophthalmology. In addition to its expertise in ophthalmology, Avellino is developing a non-invasive early cancer diagnostic that is derived from whole blood, saliva or tissue samples.
This announcement comes days before the SPAC’s extension vote on December 9. Senior Connect likely hopes that the prospect of a specific deal waiting in the wings will keep a few more shareholders around at its vote to at least see and hear more. But, since this deal is not at the “definitive agreement” stage, but a non-binding LOI, SPACInsider will not consider this deal fully “announced”. As such, it will remain in the “Searching” category until a definitive agreement is signed.
Senior Connect announced the pricing of its upsized $360 million IPO about two years ago in December 2020, and initially intended to combine with a target focused on senior health and living. The SPAC is led by CEO and Chairman Richard T. Burke alongside President and Director Isaac Applbaum, CFO and Director Ryan Burke and EVP of M&A Steven Schwartz.
Terms Tracker for the Week Ending January 27, 2022 Welcome to our weekly column where we discuss the findings from our IPO terms tracker based on the previous week’s pricings. We’re coming up on the end of January, the first month of the year, and to-date no new S-1s have been filed. Additionally, the number...
Below is a daily summary of links to the latest SPAC news and rumors gathered across the web. Latest SPAC News: Circle spokesperson denies blaming SEC for failed deal, BuzzFeed CEO says AI-powered content will be part of core business, and FaZe Clan faces possible delisting Circle Spokesperson Denies Blaming SEC for Failed $9 Billion Deal...
Health Sciences 2 (NASDAQ:HSAQ) announced that it closed its combination with Orchestra BioMed on January 26. HSAQ ahead of its vote pre-announced redemption figures of 1,597,888 shares equating to 67.7% redemptions, however, that’s still subject to change. However, today it was noted that Orchestra BioMed is to receive $70 million in gross proceeds including $20...
Carbon capture technology has long been talked about, and it is finally in operation with LanzaTech among the pioneers. Its plants are turning potential emissions into clothing, household goods and sustainable fuels. SPAC cash is now also an accelerant in this new process as the company announced a $1.7 billion combination with AMCI II last March. This week, we caught up with...
In this series we’ll be examining successful SPAC deals from the past both in the terms and circumstances of their de-SPAC processes and how they have weathered the storms that have followed after their public listings with research from SPACInsider contributor Anthony Sozzi. Thirty months does not sound like that long, but it’s been a...